News and announcements

May 15, 2019

Dr. Mitch Kling and Dr. Dayan Goodenowe to present at Prodrome Health on May 29

SeminarposterFinal3...

May 7, 2019

Prodrome Health Centre opens May 27 in Moose Jaw, Saskatchewan, Canada

We are excited to announce the opening of a new Prodrome Health Centre in Moose Jaw,

...

April 26, 2019

Prodrome Sciences Inc. and University of Pennsylvania awarded grant from the Alzheimer’s Association to investigate the effects of Prodrome Sciences’

...

April 25, 2019

Prodrome Sciences Inc. announces publication of peer-reviewed research paper linking high blood plasmalogen levels to lower risk of Alzheimer’s

...

March 20, 2019

Prodrome Sciences opens up new laboratory facility in California

We are pleased to announce the opening of our new 4,000 square foot laboratory facility in

...

March 4, 2019

Prodrome Sciences Inc. announces large-scale, Japanese colorectal cancer and pancreatic cancer biomarker study

Prodrome Sciences Inc.; Chiba University Hospital,

...

February 18, 2019

Prodrome Sciences Inc. announces its 3-year colorectal cancer screening program with collaborators in Japan is entering the final phase

Prodrome Sciences Inc.;

...

December 14, 2018

Dr. Kevin Perrott joins Prodrome Sciences to advance self-directed research programs

Prodrome Sciences is proud to announce a new board member and advisor, Dr.

...

October 19, 2018

Prodrome Sciences launches metabolomics services for contract research projects

Prodrome Sciences is pleased to announce our customizable, non-targeted,

...

September 20, 2018

Prodrome Sciences Inc. and Kyoto Prefectural University of Medicine announce biomarker discovery research relationship

Prodrome Sciences and Kyoto Prefectural

...

August 2, 2018

Dr. Dayan Goodenowe interviewed by PM360 Magazine 

Dr. Dayan Goodenowe, Prodrome Sciences' founder and CEO, was recently interviewed by PM360 Magazine. ...

July 26, 2018

Scientific American features story on plasmalogens and Alzheimer’s disease

Prodrome Sciences is pleased to see recent media coverage of the important role

...

July 24, 2018

Independent validation of Dr. Dayan Goodenowe’s original research findings linking decreased blood plasmalogens with increased risk of dementia presented at the 2018

...

July 20, 2018

Prodrome Sciences to present new multi-analyte, high-resolution/accurate-mass technology at the Japanese Society for Biomedical Mass Spectrometry Annual

...

June 13, 2018

Dr. Dayan Goodenowe to present the results of Prodrome Sciences’ Japanese population distribution study of colorectal cancer associated gastrointestinal tract acids

...

June 11, 2018

Prodrome Sciences Inc. launches blood tests in Eastern Europe

Prodrome Sciences Inc. is pleased to announce a distribution agreement with Neo Sanguis Srl for the

...

May 31, 2018

Prodrome Sciences Inc. and NK Medico announce exclusive distribution relationship for Japan

Prodrome Sciences Inc. and NK Medico are proud to announce they have

...

May 21, 2018

Prodrome Sciences Inc. and Japan’s National Center of Neurology and Psychiatry announce biomarker discovery research relationship

Prodrome Sciences Inc. and

...

January 8, 2018

Prodrome Sciences Inc. launches Prodrome-PAC – the high-resolution/accurate mass blood test to assess pancreatic cancer risk

Saskatoon, SK, Canada –

...

January 8, 2018

Prodrome Sciences Inc. launches Prodrome-CRC – the high-resolution/accurate mass blood test to assess colorectal cancer risk

Saskatoon, SK, Canada –

...

July 31, 2017

Dr. Dayan Goodenowe to present at the Neurotechnology for Discovery and Translation Symposium

Prodrome Sciences is pleased to announce that Dr. Goodenowe has been

...

May 15, 2017

Dr. Dayan Goodenowe to give public lecture on Alzheimer's disease in Prince Edward Island

Prodrome Sciences is pleased to announce that Dr. Goodenowe has been

...

June 15, 2016

Dr. Dayan Goodenowe describes the utility of prodrome diagnostic tests for population-based cancer screening at the Cancer Diagnostics Conference & Expo in Rome,

...

July 15, 2016

Dr. Dayan Goodenowe describes plasmalogen restoration therapy for the treatment of the rare genetic children’s disease rhizomelic chondrodysplasia punctata at the

...

June 15, 2016

Dr. Dayan Goodenowe describes the utility of plasmalogen based therapeutics for neurodegenerative and psychiatric disorders at the annual Canadian College of

...

July 27, 2016

Dr. Dayan Goodenowe describes the association between low blood plasmalogen levels, post-mortem brain pathology, and dementia

On July 26, 2016, Dr. Dayan

...

July 27, 2016

Dr. Dayan Goodenowe describes the association between low blood plasmalogen levels, dementia, and mortality

On July 26, 2016, Dr. Dayan Goodenowe, founder of

...

About Prodrome Sciences Inc.

Prodrome Sciences researches prodromes of diseases – how to detect them, what causes them, and how to return high-risk prodrome states back to a healthy state before the disease develops. We use our advanced diagnostic technology for blood tests to detect disease prodromes and in our natural therapeutic programs to restore an unhealthy, high-risk prodrome state to a healthy, low-risk state. Our goal is to reduce the number of people that develop and die from disease and to promote optimal health.

Keep in touch

©2019 Prodrome Sciences Inc.

Search